Clinical Research Awards


To accelerate NF research, CTF launched the Clinical Research Award (CRA) program in 2007 to support early stage pilot clinical trials of candidate therapeutics or interventions for treatment of manifestations of NF1, NF2 and schwannomatosis. In addition, these awards support innovative clinical trial enabling studies.

It is hoped that applications for Clinical Research Awards will be broad-thinking, novel ideas. Examples of projects encouraged may include but are not limited to the following:

  • Preclinical/clinical collaborative studies. Note that all studies must include a clinical element – preclinical-only studies are not eligible
  • Pilot clinical trials (CTF leverages our relationship with industry or larger funding organizations to provide drug at no cost to successful applicants.)
  • Clinical enabling studies such as biomarker and patient stratification that may better inform and help accelerate a clinical trial.

It is anticipated that CTF will fund up to three Clinical Research Awards of up to $150,000 (including overheads and indirect costs).


The Letter of Intent to the
2015 Clinical Research Awards
is now available.

The LOI due date has been extended
to Wednesday, July 1, 2015

To start a NEW application please log in HERE.

Once you begin your application, you may save it by clicking SAVE at the bottom of any page. An email will arrive with a link to return to your IN-PROGRESS application. Please do not return to the New Application link above, as none of your work will be saved.

We look forward to receiving your letter of intent!

2015 CRA Application Window

  • July 1, 2015 - LOI due (extended)
  • The week of June 29, 2015 - Invitation to full application
  • August 17, 2015 - Full application due
  • Notifications will be made in early November 2015

NF Clinical Research Awardees

2014 Funded Clinical Trial Awards

A Study of INFUSE Bone Graft (recombinant human Bone Morphogenetic Protein-2/absorbable collagen sponge) in the Treatment of Tibial Pseudoarthrosis in Neurofibromatosis 1 (NF1). Dr. Bruce Korf, University of Alabama at Birmingham

Phase 1 trial of combined MEK and mTOR inhibition in MPNSTs. Dr. Aerang Kim, Children’s Research Institute

Resiliency training for adolescents with NF1 and NF2.Dr. Ana-Maria Vranceanu, Massachusetts General Hospital

2013 Funded Clinical Trial Awards

Good manufacturing practice of clinical grade advanced-therapy medicinal product in regenerative therapy for congenital pseudarthrosis of the tibia in 5 individuals with neurofibromatosis type 1, Dr. Eric Legius

The Impact of Ras/MAPK signaling pathway-targeted therapies on neurocognitive functioning in youth with NF1, Dr. Karin Walsh, Children's Research Institute

Resiliency training for patients with Neurofibromatosis via videoconferencing with Skype, Dr. Ana-Marie Vranceanu, Massachusetts General Hospital

2012 Funded Clinical Trial Awards 

A Phase II Randomised Placebo-Controlled Double-Blind Cross-Over Trial of Methylphenidate in Children with Neurofibromatosis Type1, Dr. Kathryn North, The Children’s Hospital at Westmead

Effect of creating visual illness narratives on quality of life in children with Neurofibromatosis type 1: a pilot intervention study, Dr. Nicole Ullrich, Boston Children's Hospital

Effect of anti-VEGF and radiation on NF2 vestibular Schwannoma Schwannoma, Dr. Lei Xu, Massachusetts General Hospital                              

 2011 Funded Clinical Trial Awards 

Phase II Trial of Rapamycin - NF2 Tumors
Dr. Matthias Karajannis, New York University Langone Medical Center

New metrics for optic pathway glioma trials
Dr. Robert Avery, Children’s National Medical Center

Blood predictors of NF1 severity
Dr. Cynthia Hingtgen, Indiana University

Computerized ‘maze’ for NF1 learning disabilities trials
Dr. Nicole Ullrich, Children’s Hospital Boston

Contact Us

Children's Tumor Foundation
120 Wall Street, 16th Floor
New York, NY 10005-3904

Phone: 212-344-6633